Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/185015
Title: | Engineering pH-Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics |
Author: | Boloix, Ariadna Feiner Gracia, Natalia Kober, Marina Repetto, Javier Pascarella, Rosa Soriano, Aroa Masanas, Marc Segovia, Nathaly Vargas Nadal, Guillem Merlo Mas, Josep Danino, Dganit Abutbul-Ionita, Inbal Foradada, Laia Roma, Josep Cordoba, Alba Sala, Santi Sánchez de Toledo, Josep Gallego Melcón, Soledad Veciana, Jaume Albertazzi, Lorenzo Segura, Miguel F. Ventosa, Nora |
Keywords: | Tumors Micro RNAs MicroRNAs Tumors |
Issue Date: | 20-Jan-2022 |
Publisher: | Wiley |
Abstract: | MicroRNAs (miRNAs) are small non-coding endogenous RNAs, which are attracting a growing interest as therapeutic molecules due to their central role in major diseases. However, the transformation of these biomolecules into drugs is limited due to their unstability in the bloodstream, caused by nucleases abundantly present in the blood, and poor capacity to enter cells. The conjugation of miRNAs to nanoparticles (NPs) could be an effective strategy for their clinical delivery. Herein, the engineering of non-liposomal lipid nanovesicles, named quatsomes (QS), for the delivery of miRNAs and other small RNAs into the cytosol of tumor cells, triggering a tumor-suppressive response is reported. The engineered pH-sensitive nanovesicles have controlled structure (unilamellar), size (<150 nm) and composition. These nanovesicles are colloidal stable (>24 weeks), and are prepared by a green, GMP compliant, and scalable one-step procedure, which are all unavoidable requirements for the arrival to the clinical practice of NP based miRNA therapeutics. Furthermore, QS protect miRNAs from RNAses and when injected intravenously, deliver them into liver, lung, and neuroblastoma xenografts tumors. These stable nanovesicles with tunable pH sensitiveness constitute an attractive platform for the efficient delivery of miRNAs and other small RNAs with therapeutic activity and their exploitation in the clinics. |
Note: | Reproducció del document publicat a: https://doi.org/10.1002/smll.202101959 |
It is part of: | Small, 2022, vol. 18 |
URI: | http://hdl.handle.net/2445/185015 |
Related resource: | https://doi.org/10.1002/smll.202101959 |
ISSN: | 1613-6829 |
Appears in Collections: | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
2021_Small_Engineering_Boloix.pdf | 12.21 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License